anti-MOG antibody product blog
Tags: Antibody; Monoclonal Antibody; Myelin Oligodendrocyte Glycoprotein; anti-MOG antibody; MOG;
The MOG n/a (Catalog #MBS140089) is an Antibody produced from Mouse and is intended for research purposes only. The product is available for immediate purchase. MyBioSource\'s Myelin Oligodendrocyte Glycoprotein can be used in a range of immunoassay formats including, but not limited to, Direct ELISA (EIA), Western Blot (WB), Immunoprecipitation (IP), Immunohistochemistry (IHC).By direct ELISA, 1:10,000 dilution will yield 0.5 O.D. using alkaline phosphatase conjugated rabbit anti-mouse Ig (Jackson Laboritories). Researchers should empirically determine the suitability of the MOG n/a for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.
The MOG n/a product has the following accession number(s) (GI #168985765) (NCBI Accession #CAQ06620.1). Researchers may be interested in using Bioinformatics databases such as those available at The National Center for Biotechnology Information (NCBI) website for more information about accession numbers and the proteins they represent. Even researchers unfamiliar with bioinformatics databases will find the NCBI databases to be quite user friendly and useful.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
Physical Appearance: Sterile Filtered White lyophilized (freeze-dried) powder. Reconstitution: Reconstitute with H20. Mix gently, wash the sides of the vial and wait 30-60 seconds before use.
Immunogen: Synthetic pMOG 35-55. In general, we may offer more than one antibody to a given target to enable options for the researcher. Available antibodies recognizing MOG are readily searchable from our website. Different antibodies against the same target such as MOG may be optimized or tested for different applications and species. This enables researchers to select the option that may be best for their model system, to screen more than antibody to determine which one may be best for their model system, as well as to use more than one antibody to follow up on and validate their results.